Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
10 11 2020
Historique:
pubmed: 24 10 2020
medline: 15 12 2020
entrez: 23 10 2020
Statut: ppublish

Résumé

An essential mechanism for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection begins with the viral spike protein binding to the human receptor protein angiotensin-converting enzyme II (ACE2). Here, we describe a stepwise engineering approach to generate a set of affinity optimized, enzymatically inactivated ACE2 variants that potently block SARS-CoV-2 infection of cells. These optimized receptor traps tightly bind the receptor binding domain (RBD) of the viral spike protein and prevent entry into host cells. We first computationally designed the ACE2-RBD interface using a two-stage flexible protein backbone design process that improved affinity for the RBD by up to 12-fold. These designed receptor variants were affinity matured an additional 14-fold by random mutagenesis and selection using yeast surface display. The highest-affinity variant contained seven amino acid changes and bound to the RBD 170-fold more tightly than wild-type ACE2. With the addition of the natural ACE2 collectrin domain and fusion to a human immunoglobulin crystallizable fragment (Fc) domain for increased stabilization and avidity, the most optimal ACE2 receptor traps neutralized SARS-CoV-2-pseudotyped lentivirus and authentic SARS-CoV-2 virus with half-maximal inhibitory concentrations (IC50s) in the 10- to 100-ng/mL range. Engineered ACE2 receptor traps offer a promising route to fighting infections by SARS-CoV-2 and other ACE2-using coronaviruses, with the key advantage that viral resistance would also likely impair viral entry. Moreover, such traps can be predesigned for viruses with known entry receptors for faster therapeutic response without the need for neutralizing antibodies isolated from convalescent patients.

Identifiants

pubmed: 33093202
pii: 2016093117
doi: 10.1073/pnas.2016093117
pmc: PMC7668070
doi:

Substances chimiques

Antiviral Agents 0
Peptide Library 0
Recombinant Proteins 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

28046-28055

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM122451
Pays : United States
Organisme : NIGMS NIH HHS
ID : K12 GM081266
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA082103
Pays : United States
Organisme : NIH HHS
ID : R35 GM122451-01
Pays : United States
Organisme : NIH HHS
ID : DP2 OD022552
Pays : United States
Organisme : NIGMS NIH HHS
ID : K99 GM135529
Pays : United States
Organisme : NIGMS NIH HHS
ID : R00 GM135529
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI111825
Pays : United States

Commentaires et corrections

Type : UpdateOf
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

Competing interest statement: A.G., J.G., I.L., X.X.Z., T.K., and J.A.W. have filed a provisional patent related to this work.

Références

Anal Biochem. 2002 Aug 1;307(1):13-7
pubmed: 12137773
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Nat Biotechnol. 2017 Jul;35(7):667-671
pubmed: 28604661
PLoS Comput Biol. 2015 Sep 23;11(9):e1004335
pubmed: 26397464
Protein Eng Des Sel. 2006 May;19(5):211-7
pubmed: 16537642
MAbs. 2020 Jan-Dec;12(1):1804241
pubmed: 32804015
Protein Eng. 1996 Jul;9(7):617-21
pubmed: 8844834
Curr Opin Biotechnol. 2009 Dec;20(6):692-9
pubmed: 19889530
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14116-21
pubmed: 12381794
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
Nat Struct Mol Biol. 2019 Jun;26(6):407-414
pubmed: 31086346
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19970-4
pubmed: 19901337
Biotechnol J. 2017 May;12(5):
pubmed: 28299901
J Med Virol. 2020 Jun;92(6):595-601
pubmed: 32100877
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
N Engl J Med. 2020 Sep 3;383(10):994
pubmed: 32649078
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Sci STKE. 2004 Feb 03;2004(219):pl2
pubmed: 14872095
Protein Eng Des Sel. 2010 Apr;23(4):155-9
pubmed: 20130105
Crit Care. 2017 Sep 7;21(1):234
pubmed: 28877748
Nat Struct Mol Biol. 2020 Sep;27(9):846-854
pubmed: 32661423
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3913-8
pubmed: 23431173
J Virol. 2014 Dec;88(23):13769-80
pubmed: 25231316
Nat Chem Biol. 2014 Nov;10(11):977-83
pubmed: 25242553
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5
pubmed: 32735849
Science. 2020 Jun 12;368(6496):1274-1278
pubmed: 32404477
FEBS J. 2005 Jul;272(14):3512-20
pubmed: 16008552
Cell Res. 2013 Aug;23(8):986-93
pubmed: 23835475
Nat Commun. 2020 Apr 24;11(1):2070
pubmed: 32332765
Science. 2005 Sep 16;309(5742):1864-8
pubmed: 16166518
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Cell. 2020 May 14;181(4):905-913.e7
pubmed: 32333836
Protein Eng Des Sel. 2015 Oct;28(10):339-50
pubmed: 26386257
Viruses. 2020 May 06;12(5):
pubmed: 32384820
J Infect Dis. 2000 Dec;182(6):1774-9
pubmed: 11069253
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
Nature. 1992 Jun 4;357(6377):420-2
pubmed: 1350662
Clin Pharmacokinet. 2013 Sep;52(9):783-92
pubmed: 23681967

Auteurs

Anum Glasgow (A)

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158.

Jeff Glasgow (J)

Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158.

Daniel Limonta (D)

Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Department of Cell Biology, University of Alberta, Edmonton, AB T6G 2H7, Canada.

Paige Solomon (P)

Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158.

Irene Lui (I)

Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158.

Yang Zhang (Y)

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158.

Matthew A Nix (MA)

Department of Laboratory Medicine, University of California, San Francisco, CA 94143.

Nicholas J Rettko (NJ)

Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158.

Shoshana Zha (S)

Department of Medicine, University of California, San Francisco, CA 94143.

Rachel Yamin (R)

Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, NY 10065.

Kevin Kao (K)

Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, NY 10065.

Oren S Rosenberg (OS)

Department of Medicine, University of California, San Francisco, CA 94143.

Jeffrey V Ravetch (JV)

Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, NY 10065.

Arun P Wiita (AP)

Department of Laboratory Medicine, University of California, San Francisco, CA 94143.

Kevin K Leung (KK)

Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158.

Shion A Lim (SA)

Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158.

Xin X Zhou (XX)

Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158.

Tom C Hobman (TC)

Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Department of Cell Biology, University of Alberta, Edmonton, AB T6G 2H7, Canada.
Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2R3, Canada.

Tanja Kortemme (T)

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158.

James A Wells (JA)

Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158; jim.wells@ucsf.edu.
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH